SCHEMBL8176192

SCHEMBL8176192

CC1CN(C(=O)c2[nH]c(=O)n(C3CCCCC3)c2-c2ccccc2)C(C)CN1C(=O)OC(C)(C)C

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
OPRM1 P35372 4/20 0.40
OGFRL1 Q5TC84 4/20 0.40
OPRK1 P41145 2/20 0.40
OPRD1 P41143 3/20 0.38
CCR5 P51681 1/20 0.36
HPGDS O60760 2/20 0.36
DRD2 P14416 2/20 0.36
DRD4 P21917 2/20 0.36
DRD3 P35462 2/20 0.36
SETD7 Q8WTS6 1/20 0.35
CHRM2 P08172 1/20 0.34
CHRM4 P08173 1/20 0.34
CHRM1 P11229 1/20 0.34
CHRM3 P20309 1/20 0.34
NR1H2 P55055 4/20 0.34
NR1H3 Q13133 3/20 0.34
RXRA P19793 2/20 0.34
MEN1 O00255 1/20 0.34
KMT2A Q03164 1/20 0.34
NPSR1 Q6W5P4 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL8164930 0.89 SETD7 (0.46) OPRM1OGFRL1OPRK1OPRD1CCR5
SCHEMBL8171261 0.89 SETD7 (0.46) OPRM1OGFRL1OPRK1OPRD1CCR5
SCHEMBL885794 0.87 DRD2 (0.40) OPRM1OPRK1DRD2DRD4DRD3
SCHEMBL8163754 0.84 OPRM1 (0.49) OPRM1OGFRL1OPRK1OPRD1CCR5
SCHEMBL885494 0.82 DRD2 (0.39) DRD2DRD4DRD3CHRM2CHRM4
SCHEMBL885518 0.80 GHSR (0.39) DRD2DRD4DRD3CHRM2CHRM4
SCHEMBL885576 0.78 GHSR (0.39) DRD2DRD4DRD3CHRM2CHRM4
SCHEMBL885803 0.76 PLD1 (0.44) OGFRL1DRD2DRD4DRD3CHRM2
SCHEMBL2062636 0.76 BTK (0.44) OPRM1OGFRL1OPRD1CCR5HPGDS
SCHEMBL2064364 0.75 OPRM1 (0.41) OPRM1OGFRL1OPRD1CCR5HPGDS

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8148367-B2 Renin inhibitors TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2012-04-03 US disclosed
US-8148367-B2 Renin inhibitors TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2012-04-03 US disclosed
US-20100105665-A1 RENIN INHIBITORS TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2010-04-29 US disclosed
US-20100105665-A1 RENIN INHIBITORS TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2010-04-29 US disclosed
WO-2008089005-A2 RENIN INHIBITORS TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2008-07-24 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100105665-A1 RENIN INHIBITORS REN, ACE, AGT OPRM1 1874/4885OGFRL1 1610/4885OPRK1 888/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.